{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Citius Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"CTXR"},"Address":{"label":"Address","value":"11 COMMERCE DRIVE,FIRST FLOOR, CRANFORD, New Jersey, 07016, United States"},"Phone":{"label":"Phone","value":"+1 908 967-6677"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok(R), an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs."},"CompanyUrl":{"label":"Company Url","value":"https://www.citiuspharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alan Lader","title":"SVP, Head-Clinical Operations & Quality Assurance"},{"name":"Gary F. Talarico","title":"Executive Vice President-Operations"},{"name":"Leonard L. Mazur","title":"Chairman, Chief Executive Officer & Secretary"},{"name":"Myron S. Czuczman","title":"Chief Medical Officer & Executive Vice President"},{"name":"Preeti Singh","title":"VP-Clinical Development & Medical Affairs"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}